HUMPHREY RACHEL 4

What Happened

• Rachel Humphrey, a director of Pyxis Oncology (PYXS), was granted a derivative award on 2026-03-24 covering 45,867 shares. The Form 4 reports an acquisition price of $0.00 and shows $0 as the reported value for the transaction. This was an award (not a purchase or sale).

Key Details

• Transaction date: 2026-03-24; Filing date: 2026-03-25 (appears timely).
• Security: derivative award (reported as an option in the footnote) for 45,867 shares; reported acquisition price $0.00; reported dollar value $0.
• Shares owned after the transaction: not disclosed in the Form 4.
• Footnote: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to Humphrey’s continued service through the vesting date (Footnote F1).
• No 10b5-1 plan, tax-withholding, or late-filing flags are indicated in the filing.

Context

• This filing reports a time‑based equity award (the Form classifies it as a derivative and the footnote calls it an option). The grant does not represent an immediate market purchase or sale — the award vests one year later, at which point additional steps (and any exercise) would be required before shares are owned outright or sold. Such awards are commonly part of compensation for directors rather than a direct signal of near-term trading.